treatmentoptions4u.com

Apigy (Apixaban) available Delhi, Mumbai, Madras, Hyderabad, Bangalore India

Apigy (Apixaban) Tablet

Generic brands for Apixaban Injection  Available in India Brand Name Apigy Generic Name Apixaban Strength 2.5mg, 5mg Manufacturer Cipla Ltd

Category: , , , ,

Description

Description

This page contains brief details about the drug apixaban, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

Date of Approval

Apixaban is an anticoagulant drug that belongs to the category of medicines known as Factor Xa Inhibitors. It was approved on 28 December 2012 to prevent blood clots.

Mechanism of Action of Apixaban

It is a direct factor Xa inhibitor, which works majorly through the process of alkylation. It enters the cancer cells after getting activated by the liver and inhibits DNA synthesis. This process disrupts the normal cell cycle and DNA function, leading to arrest in cancer cell growth and multiplication.

Uses of Apixaban

Apixaban has been developed as a direct oral anticoagulant (DOACs) drug to prevent strokes and blood clots in people with atrial fibrillation, deep vein thrombosis, or pulmonary embolism.

Apixaban Dosage available

Your doctor will decide the dose and duration of Apixaban based on the disease condition. Always take this medicine as prescribed by your doctor. The recommended starting oral dose of axitinib is 2.5 mg twice daily. Take the tablet at the same time everyday, with or without food. Do not chew, crush, or break the tablet. Swallow the whole tablet with water. If you forgot to take the tablet, simply take your next dose at the scheduled time. Do not take a double dose to make up for a forgotten dose.

We can ship to :

News/Updates

References

  1. Bristol Myers Squibb/Pfizer EEIG; Electronic Medicines Compendium; [Revised:2021] [Accessed on 03/Apr/2023] https://www.medicines.org.uk/emc/files/pil.4756.pdf
  2. Highlights of prescribing information; food and drug administration. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211964s000lbl.pdf  [Accessed on 03/Apr/2023] .
  3. Annex I summary of Product Characteristics – European Medicines Agency; Available at: https://www.ema.europa.eu/en/documents/product-information/eliquis-epar-product-information_en.pdf [Accessed on 03/Apr/2023].
  4. Katherine Victoria Hurst, John Matthew O’Callaghan and Ashok Handa; ; Quick reference guide to Apixaban; Published 2017 [Accessed on 03/Apr/2023] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5513886/#__ffn_sectitle
  5. SL Greig; Apixaban: A review in venous thromboembolism; [Published:2016] [Accessed on 03/Apr/2023] https://pubmed.ncbi.nlm.nih.gov/27653758/
  6. Goodman & Gilman’s, The Pharmacological Basis of Therapeutics,Modulation of Cardiovascular Function, 12th edition, 2011, 867.
  7. Bertram.G.Katzung, Basic and Clinical Pharmacology, Drugs Used to Treat Diseases of the Blood, Inflammation, & Gout, 14th edition, 617